Study of donanemab for early alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests a monthly infusion drug called donanemab, which aims to clear amyloid plaques (a hallmark of Alzheimer's) from the brain, potentially slowing memory decline in people with early Alzheimer's disease. Participants will receive the drug as part of this study.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had gradual memory problems for at least 6 months.
- You have a diagnosis of mild cognitive impairment (MCI) or mild Alzheimer's dementia.
- A blood test shows amyloid plaques in your brain.
- You score between 20 and 28 on a standard memory test (MMSE).
- You have a study partner (friend or family member) who can accompany you to visits or be available by phone.
- You have not had previous treatment with anti-amyloid antibody drugs (like donanemab, lecanemab, or aducanumab) or an Alzheimer's vaccine.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called donanemab in people who have early signs of Alzheimer's disease (amyloid buildup in the brain) but are still thinking clearly. The goal is to see if the drug can slow or prevent cognitive decline before memory problems start.
This study compares donanemab plus usual care to usual care alone for people with early Alzheimer's symptoms, to see how well donanemab works in everyday life. You may be able to join if you have early memory or thinking problems and have a brain scan or blood test showing Alzheimer's-related changes.
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
This study tests whether a drug called donanemab can lower amyloid plaques in the brains of adults with Down syndrome who are at risk for Alzheimer's disease. The goal is to see if it can slow or prevent memory and thinking problems.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests an experimental drug, ARO-MAPT-SC, which may slow the progression of early Alzheimer's disease by targeting a protein involved in the disease. It is given as an injection under the skin and is being studied in healthy people and those with early Alzheimer's.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.